RheumNow Week in Review – 9 December 2016 Save

Dr. Jack Cush reviews highlights from this week on RheumNow.com.

1. RA pts have 2 fold CV risk (equal to DM related risks). Shouldnt Rheums be responsible for managing CV risk in RA https://t.co/EHl6p0zfFD
2. Smoking in non-RA not associated with Autoantibodies; but in RA, smoking is associated with multiple autoantibodies (RF, CCP2, CarP) https://t.co/ati1L69yYi
3. Tumor-induced osteomalacia, rare, with low serum phosphate, high Alkaline phosphatase, fatigue arthralgias, multiple fractures from FGF-23 producing mesenchymal tumors. https://t.co/i63MPJtTbK
4. PFAPA syndrome in Adults too: Periodic Fevers (q4wk), Aphthous ulcers , Pharynbitis, Cervical Adenitis, arthralgias, myalgia, N/V, abdominal pains. https://t.co/89K8ia58KT
5. Genes/SNPs that influence RA onset/risk are not predictive of drug responses or ultimate outcomes https://t.co/O1Rw7Yzl84
6. 10% of ANCA+ vasculitis developed cancer; CTX had 3x risk (vs. normals); RTX had 33% lower risk. Cancer was 4.6x more with CTX than RTX https://t.co/FLnHWzc8KA
7. BMJ study of >19k men, shows testosterone use associated with a 63% increased risk of DVT in the 1st 6mos. https://t.co/Rpy7SdtnRY
8. TAFRO syndrome: a rare inflammatory disorder with thrombocytopenia, anasarca, pleural effusion, ascites, fever; renal insufficiency, organomegaly, lymphadenopathy https://t.co/pPvbczLt96
9. Catastrophic antiphospholipid registry of 500 patients: 30% had SLE, death in 37%; renal 73%, lung 60%, half w/ CNS, heart, skin https://t.co/3fWqYlLZ4p
10. ENTRACTE study shows an equal CV Risk with Actemra vs Enbrel in RA patients
11. Key Lessons from the TNF Inhibitor Head-to-Head EXXELERATE Study
12. Is ABT-494 the Next JAK Inhibitor?